GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBQ

INJECTION, SOLUTION (RADIOPHARMACEUTICAL)

**4.2. Posology and method of administration** This pharmaceutical product is for use in designated nuclear medicine facilities only, and should only be handled by specialists experienced with _in vitro_ radiolabelling. Posology The quantity of the eluate gallium (68Ga) chloride solution required for radiolabelling and the quantity of 68Ga-labelled pharmaceutical product that is subsequently administered will depend on the pharmaceutical product that is radiolabelled and its intended use. Refer to the package insert of the particular pharmaceutical product to be radiolabelled. _Paediatric population_ Please refer to the package insert of the 68Ga-labelled pharmaceutical product for more information concerning its paediatric use. Method of administration The gallium (68Ga) chloride solution is not intended for direct use in patients but is used for _in vitro_ radiolabelling of various carrier molecules. The route of administration of the final pharmaceutical product should be adhered to. For instructions on extemporary preparation of the pharmaceutical product before administration, see section 10 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.